[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"atopic-dermatitis-eczema\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:atopic-dermatitis-eczema":110},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,15,0,[8,43,66,94,130,153,184,207,235,258,287,315,339,365,387],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100642524","global-healthcare-study-on-atopic-dermatitis-100642524",false,"NCT07659756","Global Healthcare Study on Atopic Dermatitis","GHSAD","Inclusion Criteria:\n\n* Signed General Consent Form, or equivalent document\n* Confirmed diagnosis of Atopic Dermatitis\n\nExclusion Criteria:\n\n* Inability to provide informed consent.\n* Datasets with ambiguous or unclear diagnosis.","ALL","14 Years",{"count":19,"type":20},9600,"ESTIMATED","5 Years","OBSERVATIONAL","The Global Healthcare Study on Atopic Dermatitis (GHSAD) is an international, multicenter observational study hosted by the University of Zurich (UZH) investigating healthcare access, treatment patterns, disease severity, and quality of life in patients with atopic dermatitis. The study collects standardized clinical data from routine medical records to identify disparities in healthcare delivery and outcomes across different healthcare systems.",[25,26],"Atopic Dermatitis (AD)","Atopic Dermatitis (Eczema)",[28,14,29],"Dermastudy","GHRSD","RECRUITING","2026-06-15",{"date":33,"type":34},"2026-06-22","ACTUAL",{"date":36,"type":34},"2025-01-01",{"date":38,"type":20},"2029-12-31",{"name":40,"class":41},"Julia Tatjana Maul","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":50,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":52,"targetDuration":54,"studyType":22,"phases":4,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":42},"100637057","assessment-of-cfdna-sting-axis-as-a-potential-pathological-marker-in-atopic-dermatitis-100637057","NCT07573735","Assessment of cfDNA-STING Axis as a Potential Pathological Marker in Atopic Dermatitis","An Observational Study on the Correlation Between Circulating Cell-free DNA and Skin Macrophage STING Pathway Activation in Patients With Atopic Dermatitis","Inclusion Criteria:\n\n* Age 18 years or older\n* Confirmed diagnosis of Atopic Dermatitis\n\nExclusion Criteria:\n\n* Use of systemic immunosuppressants, systemic corticosteroids, or biological agents within 4 weeks prior to enrollment\n* Use of topical treatments within 2 weeks prior to enrollment",true,"18 Years",{"count":53,"type":20},80,"1 Day","Study Overview Atopic dermatitis (AD), commonly known as eczema, is a chronic inflammatory skin condition characterized by intense itching and skin barrier damage. While researchers know that the immune system is overactive in AD, it is difficult to measure the exact level of \"damage\" or \"inflammation\" happening deep within the skin using only a physical exam.\n\nThe Purpose of This Study This study investigates a specific \"danger signal\" called circulating cell-free DNA (cfDNA). When skin cells are damaged or die due to inflammation, they release tiny fragments of DNA into the bloodstream. The investigators believe these fragments might act as a trigger for the immune system, worsening the disease.\n\nWhat the Study Involves Researchers will collect blood samples and small skin biopsies from patients with AD and healthy volunteers.\n\nThe study aims to: Compare the levels of cfDNA in the blood of AD patients versus healthy individuals. Determine if higher levels of cfDNA correlate with more severe skin symptoms (measured by scores like SCORAD and EASI). Examine how immune cells in the skin (macrophages) respond to these DNA fragments through a specific biological switch called the STING pathway.\n\nPotential Impact By understanding this \"damage-signal\" loop, this research may lead to new ways for doctors to monitor AD severity through simple blood tests and could identify new targets for future anti-inflammatory treatments.",[26],"2026-06-09",{"date":59,"type":34},"2026-06-11",{"date":61,"type":34},"2026-02-01",{"date":63,"type":20},"2026-07-31",{"name":65,"class":41},"Zhongda Hospital",{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":50,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":73,"targetDuration":4,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":81,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":88,"completionDateStruct":89,"leadSponsor":91,"locationsCount":93},"100630450","phase-4-the-impact-of-salt-intake-on-sodium-in-the-skin-and-inflammatory-skin-disease-100630450","NCT07487831","The Impact of Salt Intake on Sodium in the Skin and Inflammatory Skin Disease","SIS-ISD","Inclusion Criteria:\n\n* Participants ages 18 years\n* Willing and able to undergo non-contrast MRI.\n\nExclusion Criteria:\n\n* Contraindications to MRI (such as cardiac pacemakers, claustrophobia, non-compatible intracranial vascular clips, IUDs, or other implants)\n* A cardiac event in the past 6 months\n* Impaired function of the liver or kidney (glomerular filtration rate \\\u003C60 mL\u002Fmin)\n* Medications that influence sodium excretion (e.g., diuretics or SGLT2 inhibitors)\n* Antibiotic or immunomodulatory medications within the last month\n* Contraindications to sodium tablets\n\n(Topical medications used exclusively on the head\u002Fneck or hands\u002Ffeet (e.g., antifungal nail treatment, antidandruff shampoo, acne cleansers) are acceptable. Topical and systemic eczema treatments are acceptable if the participant has been on a stable dose for at least 2 months and still meets the severity entry criteria. Patients on dupilumab will not be excluded if they have been on dupilumab for at least two months and still meet the disease severity inclusion criteria.)",{"count":74,"type":20},50,"INTERVENTIONAL",[77],"PHASE4","The goal of this clinical trial is to demonstrate the feasibility of a trial that examines the impact of changes in dietary sodium intake on skin sodium levels, atopic dermatitis, and psoriasis. In addition, it aims to generate preliminary data to begin to answer the following questions:\n\n1. Is there an association between skin sodium concentration and atopic dermatitis and psoriasis severity?\n2. Are changes in dietary sodium are associated with changes in skin sodium concentration and atopic dermatitis and psoriasis severity?\n\nResearchers will compare sodium tablets to a placebo (a look-alike substance that contains no drug) to specifically examine the impact of altering sodium intake.\n\nParticipants will:\n\n* Follow a low-salt diet for the duration of the 13-week study\n* Take sodium chloride tablets every day for 5 weeks followed by a placebo every day for 5 weeks after a 2-week washout period, or vice versa\n* Visit the clinic up to 4 times to answer questionnaires, provide bio samples, complete dietary recalls, and undergo non-contrast sodium MRI",[26,80],"Psoriasis",[82,83,84],"sodium","salt","diet","NOT_YET_RECRUITING","2026-06-05",{"date":57,"type":34},{"date":33,"type":20},{"date":90,"type":20},"2028-03-17",{"name":92,"class":41},"University of California, San Francisco",2,{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":100,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":102,"enrollmentInfo":103,"targetDuration":4,"studyType":75,"phases":105,"briefSummary":107,"conditions":108,"keywords":112,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":129},"100595857","phase-2-a-study-to-evaluate-the-efficacy-and-safety-of-img-007-in-adult-participants-with-moderate-to-severe-atopic-dermatitis-100595857","NCT07037901","A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis","A Phase 2b, Multicenter, Randomized, Double-blinded, Placebo-controlled, Parallel-group, Dose-finding Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis","ADAPTIVE","Key Inclusion Criteria:\n\n* Moderate-to-severe AD\n* Documented history of inadequate response or lack of tolerability to a stable regimen of one or more topical treatment before the Screening visit, or for whom topical treatments are otherwise inadvisable\n* Female participants who are not pregnant or breastfeeding and meet at least one of the following conditions: not of childbearing potential or of childbearing potential and agrees to use a highly effective method of contraception\n* Male participants must agree to use a highly effective method of contraception\n* EASI score ≥16\n* vIGA-AD score ≥3\n* ≥10% body surface area (BSA) of AD involvement\n* Mean peak pruritus numerical rating scale ≥ 4 during 7-days before randomization\n\nKey Exclusion Criteria:\n\n* Positive hepatitis B, hepatitis C, or human immunodeficiency virus infection\n* Evidence of active or latent tuberculosis (TB)\n* History of untreated or inadequately treated TB infection\n* Active infection requiring treatment with systemic antibiotics, antivirals, antifungals, antiparasitics or antiprotozoals\n* Active unstable pruritic skin conditions in addition to AD that would interfere with the assessment of AD based on the investigator's clinical judgement\n* Other conditions or laboratory abnormality that could increase the risk associated with study participation or could interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into the study\n* Having received any of the specified therapies within the specified timeframe(s) prior to the Baseline visit","74 Years",{"count":104,"type":20},405,[106],"PHASE2","The purpose of this study is to evaluate the efficacy and safety of different dose regimens of IMG-007, compared to placebo.",[109,110,111],"Atopic Dermatitis","Atopic Dermatitis Eczema","Eczema",[113,109,114,115,111,116,117,118],"IMG-007","Dermatitis, Atopic","Dermatitis","Skin Diseases","Immune System Diseases","Dermatologic Agents","2026-05-22",{"date":121,"type":34},"2026-05-27",{"date":123,"type":34},"2025-06-17",{"date":125,"type":20},"2028-08",{"name":127,"class":128},"Inmagene LLC","INDUSTRY",23,{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":134,"acronym":135,"eligibilityCriteria":136,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":137,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":138,"conditions":139,"keywords":140,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":42},"100636667","evaluation-by-confocal-reflectance-microscopy-of-the-skin-structure-of-patients-with-atopic-dermatitis-treated-with-tralokinumab-biotherapy-100636667","NCT07568665","Evaluation by Confocal Reflectance Microscopy of the Skin Structure of Patients With Atopic Dermatitis Treated With Tralokinumab Biotherapy.","ADUTERCoM","Inclusion Criteria:\n\n* Patients aged 18 years and older.\n* Patients with moderate-to-severe Atopic Dermatitis who require systemic treatment with tralokinumab in the investigator's opinion.\n* Patients affiliated with or entitled to a social security scheme.\n* Patients capable of giving informed consent.\n* Patients who have received informed information about the study and have co-signed an informed consent form for participation in the study, along with the investigator.\n\nExclusion Criteria:\n\n* Patients who refuse to participate in the study and legally incapacitated adults\n* Patients with an uncontrolled chronic disease that may require corticosteroid courses\u002Ftreatment.\n* Patients with a severe concomitant disease that, in the investigator's opinion, would negatively affect participation in the study.",{"count":5,"type":20},"Atopic dermatitis (AD) is a chronic inflammatory skin disease with pruritus and recurrence of eczematous eruptions. Evaluation of response to treatment are only clinical using Eczema Area Severity Index (EASI), SCOring of Atopic Dermatitis Index (SCORAD) scores, with a risk of intra-observer variations. Tralokinumab is a fully human anti-IL-13 monoclonal antibody that has proven to be effective and well-tolerated for the treatment of patients with moderate-to-severe AD. Reflectance confocal microscopy (RCM) is a noninvasive procedure that allows to evaluate epidermis and papillary dermis at a cellular level. RCM allows skin structural and inflammatory parameters evaluation.\n\nThe aim of this study is to evaluate by RCM skin modifications of AD patients treated with tralokinumab.",[25,26],[141,142,143],"atopic dermatis","Reflectance Confocal Microscopy","tralokinumab","2026-04-28",{"date":146,"type":34},"2026-05-06",{"date":148,"type":34},"2025-11-27",{"date":150,"type":20},"2028-11-01",{"name":152,"class":41},"Hôpitaux Drôme Nord",{"id":154,"slug":155,"hasResults":11,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":4,"eligibilityCriteria":159,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":160,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":161,"conditions":162,"keywords":166,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":181,"locationsCount":42},"100627417","atopic-dermatitis-treated-with-dupilumab-and-jak-inhibitors-in-costa-rica-100627417","NCT07448363","Atopic Dermatitis Treated With Dupilumab and JAK Inhibitors in Costa Rica","National Registry of Patients With Atopic Dermatitis Under Treatment With Dupilumab and JAK Inhibitors Within the Costa Rican Social Security System","Inclusion Criteria:\n\n* Clinical diagnosis of atopic dermatitis according to accepted diagnostic criteria\n* Moderate-to-severe disease requiring systemic or advanced therapy\n* Receiving systemic immunosuppressive, biologic, or other advanced treatment as part of routine care\n* Evaluated in participating dermatology centers in Costa Rica\n* Available clinical records with baseline and follow-up information\n\nExclusion Criteria:\n\n* Lack of sufficient clinical data for severity or treatment assessment",{"count":74,"type":20},"The goal of this observational registry is to characterize the clinical features, severity, treatments, and outcomes of patients with atopic dermatitis in Costa Rica receiving systemic and advanced therapies in routine clinical practice. The main questions it aims to answer are:\n\nWhat are the demographic and clinical characteristics of patients with moderate-to-severe atopic dermatitis treated in specialized dermatology centers in Costa Rica?\n\nWhat treatments are used in real-world practice and how do they impact disease severity and patient-reported outcomes over time?\n\nParticipants with atopic dermatitis receiving systemic or advanced therapies as part of their usual medical care will be followed longitudinally, with collection of clinical severity scores, treatment patterns, and outcomes during routine visits.",[109,25,26,163,164,165],"Atopic Dermatitis Patients","Atopic Dermatitis \u002F Eczema","Atopic Dermatitis, Unspecified",[167,168,169,170,171,172,173],"Registry","Dupilumab","Abrocitinib","Upadacitinib","JAK-inhibitor","Atopic dermatitis","Baricitinib","2026-04-02",{"date":176,"type":34},"2026-04-08",{"date":178,"type":20},"2026-05",{"date":180,"type":20},"2031-05",{"name":182,"class":183},"Caja Costarricense de Seguro Social","OTHER_GOV",{"id":185,"slug":186,"hasResults":11,"nctId":187,"briefTitle":188,"officialTitle":189,"acronym":190,"eligibilityCriteria":191,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":192,"targetDuration":4,"studyType":75,"phases":194,"briefSummary":195,"conditions":196,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":199,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":205,"locationsCount":42},"100626881","phase-2-study-to-evaluate-soquelitinib-in-participants-with-moderate-to-severe-ad-100626881","NCT07441395","Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD","A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Moderate to Severe Atopic Dermatitis (SIERRA1)","SIERRA1","Inclusion Criteria:\n\n* Adult male or female, ≥18 years of age, as applicable according to local legislation, at Screening.\n* Diagnosis of AD with onset of symptoms at least 1 year prior to the Screening visit.\n* Moderate to severe disease at screening and pre-randomization on Day 1 defined by:\n* EASI ≥16\n* Body surface area ≥10%\n* vIGA ≥3\n* PP-NRS average score of ≥4 over a period of 7 days prior to randomization at Day 1.\n* Documented history of prior topical and\u002For systemic therapy for AD within 6 months of randomization.\n* A female participant is eligible if she is not pregnant or breastfeeding, and is either of non-childbearing potential, OR of childbearing potential and agrees to use highly effective birth control\n\nExclusion Criteria:\n\n* Other concomitant skin conditions that would interfere with evaluations of the effect of study medication on AD.\n* Other active skin diseases or skin infections (bacterial, fungal, or viral) requiring systemic treatment within 30 days of the Baseline visit or that could interfere with the appropriate assessment of AD lesions.\n* Known immunodeficiency syndrome, history of an invasive infection or active non skin-related infection requiring systemic anti-infective treatment within 30 days of Baseline.\n* History of immunosuppression not related to medication, history of clinically significant medical conditions, or any other reason which in the opinion of the investigator would interfere with the participant's participation in this study.\n* Have an unstable or uncontrolled illness, including but not limited to cerebrocardiovascular, respiratory, gastrointestinal, endocrine, hematologic, or neurologic disorders that would potentially affect participant safety within the study or confound efficacy and safety assessments.",{"count":193,"type":20},200,[106],"The main purpose of this study is to see how well different doses of soquelitinib work in participants with atopic dermatitis (AD) as compared to a placebo (pill with no medicine in it). To check this, the study doctors will examine participants' skin regularly to track how their AD changes during the study.\n\nThe study doctors will see how safe soquelitinib is by tracking side effects among participants. They will also check \"tolerability,\" which means how well the participants can handle soquelitinib and whether any potential side effects are manageable for them.\n\nTo understand how well soquelitinib works, it will be compared with a placebo. Placebo is a substance that looks like soquelitinib but contains no active medicine in it.\n\nParticipants will:\n\n* Take study treatment (soquelitinib or placebo) every day for 12 weeks\n* Visit the clinic for check-ups and tests every week for the first 2 weeks then every 2 weeks during the treatment period, and then return for follow-up visits 30, 60, and 90 days after the last dose of study treatment",[109,110,111,197],"Eczema, Atopic","2026-03-03",{"date":200,"type":34},"2026-03-05",{"date":202,"type":20},"2026-02",{"date":204,"type":20},"2027-09",{"name":206,"class":128},"Corvus Pharmaceuticals, Inc.",{"id":208,"slug":209,"hasResults":11,"nctId":210,"briefTitle":211,"officialTitle":212,"acronym":4,"eligibilityCriteria":213,"healthyVolunteers":11,"sex":16,"minAge":214,"maxAge":51,"enrollmentInfo":215,"targetDuration":4,"studyType":75,"phases":217,"briefSummary":219,"conditions":220,"keywords":221,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":226,"lastUpdatePostDateStruct":227,"startDateStruct":229,"completionDateStruct":231,"leadSponsor":233,"locationsCount":42},"100613774","moisturization-and-skin-hydration-study-100613774","NCT07270965","Moisturization and Skin Hydration Study","Understanding the Effect of Pre-Drying Moisturization on Skin Hydration","Inclusion Criteria:\n\n* Participants must have a diagnosis of atopic dermatitis\u002Feczema.\n* Participants must be between the age of 12-18.\n* Participants must be able to bathe independently.\n* Participants will be English speaking and able to complete questionnaires.\n\nExclusion Criteria:\n\n* Participants who use topical corticosteroids between one inch above the wrist and 1 inch below the elbow from 1 month on both arms prior to the study until the final visit.\n* Participants who have a known allergy to the moisturizer cream (Cerave Moisturizing Cream) provided.","12 Years",{"count":216,"type":20},30,[218],"NA","Skin moisturization is important for patients with atopic dermatitis, commonly known as eczema. Moisturizing right after bathing is widely accepted as the best method to keep skin hydrated. However, there is conflicting research on the timing of moisturizing. The goal of this clinical study is to evaluate the preference of moisturizing while showering\u002Fbathing compared to after towel drying in adolescents aged 12-18 with eczema. The main question it aims to answer are:\n\n* Which moisturization technique is preferred: while showering\u002Fbathing or after towel drying?\n* How do these techniques affect investigator-assessed eczema severity, patient-reported itch scores, and objective skin hydration measurements?\n\nResearchers will compare applying moisturizer while in the shower\u002Fbath to after towel drying and to which technique is preferred among participants and if there are different effects on eczema and skin hydration.\n\nParticipants will:\n\n* Apply moisturizer while showering\u002Fbathing for one month and after towel drying for one month.\n* Complete questionnaires on moisturization technique, skin feel, and itchiness.\n* Undergo skin hydration measurements using a Corneometer® CM825 device.",[25,26],[109,111,222,223,224,225],"AD","Moisturizer","Cream","Skin Hydration","2025-12-03",{"date":228,"type":34},"2025-12-08",{"date":230,"type":20},"2025-12",{"date":232,"type":20},"2026-12",{"name":234,"class":41},"University of British Columbia",{"id":236,"slug":237,"hasResults":11,"nctId":238,"briefTitle":239,"officialTitle":240,"acronym":241,"eligibilityCriteria":242,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":243,"targetDuration":4,"studyType":75,"phases":245,"briefSummary":246,"conditions":247,"keywords":248,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":250,"startDateStruct":252,"completionDateStruct":254,"leadSponsor":256,"locationsCount":93},"100516474","phase-4-dupilumab-dose-reduction-in-patients-with-controlled-atopic-eczema-100516474","NCT06004986","DUPIlumab Dose REDUCtion in Patients With Controlled Atopic Eczema","DUPI REDUCE Trial (DUPIlumab Dose REDUCtion in Patients With Controlled Atopic Eczema): a Multicenter, Low-intervention, Non-inferiority Randomized Controlled Trial, Embedded in the TREAT NL Registry","DUPI REDUCE","Inclusion Criteria:\n\n* The subject is an adult,\n* Has a diagnosis of AE,\n* Receives dupilumab 300 mg q2w for the treatment of AE,\n* Has controlled disease according to the Treat-to-Target criteria,\n* Agrees to the possibility that the dosage of dupilumab will be lowered,\n* Has voluntarily signed and dated an informed consent prior to any study related procedure.\n\nExclusion Criteria:\n\n* The subjects uses or initiates another systemic immunomodulating therapy for AE or another diagnosis.",{"count":244,"type":20},216,[77],"The goal of this randomized controlled trial is to study the (cost)effectiveness of extending the intervals between dupilumab doses in patients with well-controlled atopic eczema, while considering physician- and patient-reported disease severity, quality of life, and dupilumab serum trough levels. Patients will be divided randomly into three groups, receiving dupilumab 300 mg every 2 weeks, every 3 weeks, or every 4 weeks. Researchers will then compare the outcomes among these three groups.",[109,110],[168],"2025-10-06",{"date":251,"type":34},"2025-10-08",{"date":253,"type":34},"2023-08-14",{"date":255,"type":20},"2025-12-31",{"name":257,"class":41},"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)",{"id":259,"slug":260,"hasResults":11,"nctId":261,"briefTitle":262,"officialTitle":263,"acronym":4,"eligibilityCriteria":264,"healthyVolunteers":50,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":265,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":267,"conditions":268,"keywords":274,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":278,"lastUpdatePostDateStruct":279,"startDateStruct":281,"completionDateStruct":283,"leadSponsor":285,"locationsCount":42},"100602250","validation-of-a-parent-administered-symptom-score-for-unsettled-infants-every-baby-is-unique-100602250","NCT07121062","Validation Of A Parent Administered Symptom Score For Unsettled Infants (Every Baby is UnIQue)","Validation Of A Parent Administered Symptom Score For Unsettled Infants","Inclusion Criteria:\n\n1. Consent to complete the anonymous questionnaire\n2. Parent 18 years old or over\n3. Parent of an infant aged under 12 months old at time of questionnaire completion\n\nExclusion Criteria:\n\n1. Parent does not consent to complete the anonymous questionnaire\n2. Parent under 18 years old\n3. Parent of an infant aged 12 months or older at time of questionnaire completion",{"count":266,"type":20},350,"It's common for infants to be unsettled, especially in the first few months of life. While this is often normal, persistent symptoms can be stressful for families. Parents naturally seek explanations, and common suspected causes include colic, reflux, eczema, and cow's milk allergy (CMA). However, CMA is frequently over diagnosed, which can lead to unnecessary changes such as stopping breastfeeding or switching to expensive specialist formulas.\n\nTo address this, we've developed an online questionnaire to help track and understand symptoms in unsettled infants. Our long-term goal is to use this tool to support more accurate diagnosis of CMA. Before that, we need to test and validate the questionnaire in a general population of infants, including those who are healthy and those with other temporary conditions like a recent immunisation or teething.\n\nThis study involves an anonymous online survey for parents of babies under 12 months old. We aim to collect data from approximately 350 participants. The study will help us assess how well the questionnaire reflects the severity of symptoms and whether it can distinguish between healthy infants and those with underlying issues.\n\nParents will be invited to take part using flyers with a QR code distributed in various healthcare settings, including GP clinics and children's clinics in hospital. The survey is anonymous and hosted on a secure platform. While we don't anticipate the questions to be distressing, we recognise some may touch on sensitive topics. Support resources and study team contact details will be provided.\n\nBy validating this tool, we hope to improve how unsettled behaviour in infants is assessed-reducing unnecessary interventions and better supporting families and healthcare professionals.",[269,270,271,26,272,273],"Colic, Infantile","Milk Allergy, Cow's","Gastro Oesophageal Reflux Disease","Constipation - Functional","Congential Hip Dysplasia",[275,276,277],"Infantile colic","Cows milk allergy","Unsettled behaviour","2025-08-06",{"date":280,"type":34},"2025-08-13",{"date":282,"type":20},"2025-09",{"date":284,"type":20},"2026-08",{"name":286,"class":41},"University Hospital Southampton NHS Foundation Trust",{"id":288,"slug":289,"hasResults":11,"nctId":290,"briefTitle":291,"officialTitle":292,"acronym":293,"eligibilityCriteria":294,"healthyVolunteers":11,"sex":16,"minAge":295,"maxAge":4,"enrollmentInfo":296,"targetDuration":4,"studyType":75,"phases":298,"briefSummary":299,"conditions":300,"keywords":301,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":305,"lastUpdatePostDateStruct":306,"startDateStruct":308,"completionDateStruct":310,"leadSponsor":312,"locationsCount":314},"100581856","phase-2-phase-2-randomized-double-blind-study-to-assess-topical-zabalafin-hydrogel-vs-vehicle-in-mild-to-moderate-ad-100581856","NCT06855745","Phase 2 Randomized Double-blind Study to Assess Topical Zabalafin Hydrogel Vs Vehicle in Mild to Moderate AD.","A Phase 2, Randomized, Double-blind, Multicenter Study to Assess the Safety and Efficacy of Topical Zabalafin Hydrogel Versus Vehicle in the Treatment of Participants With Mild to Moderate Atopic Dermatitis (CLEAR-AD1)","CLEAR-AD1","Inclusion Criteria:\n\n1. Male\u002Ffemale participants who are ≥2 years of age on the day of providing documented informed consent\u002Fassent.\n2. Have a clinical diagnosis of Atopic Dermatitis (AD) according to the criteria of Hanifin and Rajka (1980) at the Screening visit and a history of AD for at least 6 months (3 months for children under the age of 6).\n3. Mild to moderate AD indicated by vIGA (Validated Investigator's Global Assessment) score of 2 (mild) or 3 (moderate) at Screening and at Day 1 prior to application of study intervention.\n4. Have AD on the head (including face, but excluding hair-bearing scalp), neck, trunk (excluding groin and genitals), or limbs, covering at least ≥2% of total BSA (body surface area) and not more than 20% at Screening and at Day 1 (Visit 1).\n5. Participants who have at least 1 lesion that measures approximately 5 cm2 or more at Screening and Day 1. Lesion must be representative of the participant's atopic dermatitis and not be located on the hands, feet, or genitalia.\n6. Have an Eczema Area and Severity Index (EASI) total score of ≥3 to ≤21 at Screening and at Day 1.\n7. Have a peak pruritus Numeric Rating Scale (NRS) score of at least 4 at Screening and at Day 1.\n8. All allowed oral and topical medications (Protocol Section 6.5) must be stable regimens within the 14 days prior to Day 1.\n9. Willing to refrain from using any topical products, including cosmetics and skin cleansers on the AD lesions during the study intervention application period (Section 6.5.1).\n10. Participants who are willing and able to comply with all study procedures, including scheduled visits, proper administration of study intervention application, lifestyle considerations.\n11. A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:\n\n    * Not a woman of childbearing potential (WOCBP) OR\n    * A WOCBP who agrees to follow the contraceptive guidance in Section 10.4. Male participants are eligible to participate if they agree to follow the contraceptive guidance\n\nExclusion Criteria:\n\n1. Unstable course of AD (spontaneously improving or rapidly deteriorating) as determined by the investigator in the 4 weeks prior to Day 1.\n2. Concurrent conditions and history of other diseases:\n\n   1. Any other concomitant skin disorder, pigmentation, or extensive scarring that, in the opinion of the investigator, may interfere with the evaluation of AD lesions or compromise participant safety.\n   2. The presence of AD lesions only on the hands or feet without prior history of involvement of other classical areas of involvement such as the face or the folds.\n   3. Other types of atopic dermatitis.\n3. Has recent or anticipated concomitant use of systemic or topical therapies that might alter the course of AD in the opinion of the investigator\n4. Ultraviolet (UV) light therapy or prolonged exposure to artificial sources of UV radiation within 2 weeks prior to Screening and\u002For intention to have such exposure during the study.\n5. Use of any of the following treatments within the indicated washout period before Day\n\n   1. 5 half-lives or 12 weeks, whichever is longer - biologic agents (e.g. dupilumab).\n   2. 4 weeks - systemic corticosteroids or adrenocorticotropic hormone analogs, cyclosporin, methotrexate, azathioprine, or other systemic immunosuppressive or immunomodulating agents (e.g. mycophenolate or tacrolimus).\n   3. Two weeks - systemic antibiotics.\n   4. One week - use of other topical treatments for AD (other than bland emollients).\n   5. One week - topical antiviral agents, topical antibacterial agents, topical antifungal agents, topical corticosteroid agents.\n   6. One week - oral antibiotics\n6. Has undergone treatment within 5 years for any cancer except non-melanoma skin cancers, squamous cell carcinoma, basal cell carcinoma. Participants with adequately treated or excised non-metastatic basal cell or squamous cell cancer of the skin, or cervical carcinoma in situ are allowed.\n7. Active or potentially recurrent dermatologic condition other than AD that may confound evaluation in the opinion of the investigator.\n8. Current or recent history (within 3 months) of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, metabolic, endocrine, pulmonary, cardiovascular, or neurological disease.\n9. Have had a systemic infection within the past 3 months requiring hospitalization.\n10. Have required the use of parenteral antimicrobial, antivirals, antiprotozoals, antifungals, janus kinase inhibitors (JAK), tyrosine kinase inhibitors (TYK2, or phosphodiesterase 4 (PDE4) inhibitors, monoclonal antibodies (mABs), or other parenteral therapies as judged to be clinically significant by the Investigator within the past 3 months.\n11. Has undergone significant trauma or major surgery within 3 months prior to screening or has major surgery planned during the study.\n12. Known hypersensitivity to zabalafin or any component of the hydrogel vehicle.\n13. Has a presence of depression per the Depression and Anxiety Disorder Score (DASS) scale that is not controlled with medication or is in remission, or the presence of severe depression or suicidal ideation or behavior. Participants with severe depression\u002Fsuicidal ideation\u002Fbehavior should be referred to appropriate medical professionals for evaluation.\n14. A WOCBP who has a positive serum pregnancy test within 24 hours prior to randomization or treatment allocation.\n\n    Note: If 24 hours have elapsed between the screening pregnancy test and the first dose of study intervention, another serum pregnancy test must be performed and must be negative for participant to start receiving study intervention.\n15. Has received a live or live-attenuated vaccine within 30 days prior to the first dose of study intervention. Administration of killed vaccine and mRNA vaccines are allowed.\n\n    Note: Any licensed COVID-19 vaccine (including for Emergency Use) is allowed in the study if they are Messenger Ribonucleic Acid (mRNA) vaccines, replication-incompetent adenoviral vaccines, or inactivated vaccines. These vaccines will be treated just as any other concomitant therapy. Investigational vaccines (ie, those not licensed or approved for Emergency Use) are not allowed.\n\n    Prior\u002FConcurrent Clinical Study Experience:\n16. Current treatment or treatment within 90 days or 5 half-lives (whichever is longer) before Day 1 with another investigational medication or current enrollment in another investigational drug protocol.\n\n    Other Exclusion Criteria:\n17. Investigator site staff members directly involved in the conduct of the study and their family members; site staff members otherwise supervised by the investigator, are not eligible.\n18. Has a history of alcohol or substance abuse within 6 months prior to Screening that in the opinion of the investigator will preclude participation in the study.\n19. Have any medical or psychiatric condition which, in the opinion of the Investigator or the Sponsor's Medical Monitor, would place the participant at risk, interfere with participation in the study, or interfere with the interpretation of study results.","2 Years",{"count":297,"type":20},72,[106],"A Phase 2b study investigating the efficacy of zabalafin in people with mild to moderate atopic dermatitis (eczema).",[26,110,109,25,111,197],[111,302,303,222,115,304],"Childhood eczema","Adult eczema","Infected dermatitis","2025-07-30",{"date":307,"type":34},"2025-08-01",{"date":309,"type":34},"2025-03-25",{"date":311,"type":20},"2025-11-28",{"name":313,"class":128},"Alphyn Biologics",12,{"id":316,"slug":317,"hasResults":11,"nctId":318,"briefTitle":319,"officialTitle":320,"acronym":4,"eligibilityCriteria":321,"healthyVolunteers":11,"sex":16,"minAge":322,"maxAge":323,"enrollmentInfo":324,"targetDuration":4,"studyType":75,"phases":326,"briefSummary":327,"conditions":328,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":330,"lastUpdatePostDateStruct":331,"startDateStruct":333,"completionDateStruct":335,"leadSponsor":337,"locationsCount":93},"100564981","prebiotic-effects-of-mulberry-fruit-in-children-and-adolescents-with-atopic-dermatitis-100564981","NCT06636240","Prebiotic Effects of Mulberry Fruit in Children and Adolescents With Atopic Dermatitis","Study on the Potential Prebiotic Effects and Gut Microbiota Changes of Glucoside-enriched Mulberry Fruit in Children and Adolescents With Atopic Dermatitis","Inclusion Criteria:\n\n* Aged 6 years and above (including 6 years) to less than 18 years (excluding 18 years)\n* The legal guardian has the ability to understand and is willing to sign the written informed consent document\n* Diagnosed by a physician according to the international Hanifin \\& Rajka criteria for atopic dermatitis, with a confirmed diagnosis of more than six months\n\nExclusion Criteria:\n\n* Allergic to berries, mulberries, fruits from the same family (such as figs), or similar chemical or biological components\n* Patients with immunodeficiency, including congenital or acquired immune disorders\n* Patients with immune-related diseases other than allergies, asthma, or allergic rhinitis, including malignancies, rheumatic diseases, lupus erythematosus, chronic liver diseases, cirrhosis, kidney diseases, diabetes, or asplenia\n* Individuals with other diseases or mental disorders that prevent them from complying with the intervention plan\n* Patients with Short Bowel Syndrome\n* Received oral or injectable antibiotics in the past month\n* Received immunomodulators, biologics, or oral\u002Finjectable steroids exceeding 2 mg\u002Fkg\u002Fday in the past three months\n* Underwent major surgery within 28 days before the study intervention (including the 28th day) or have not recovered from the side effects or complications of drug treatment\u002Fsurgery from four weeks prior\n* Currently participating in other drug intervention studies\n* Currently experiencing systemic infection or unexplained fever (ear temperature greater than or equal to 38°C)\n* Pregnancy\n* Premature infants (born before 37 weeks, excluding 37 weeks)\n* Individuals with congenital diseases, nutritional or metabolic disorders, or keratinization disorders\n* Diagnosed with malignancies within the past five years.","6 Years","17 Years",{"count":325,"type":20},120,[218],"This project proposes a randomized controlled human study to explore the prebiotic effects of consuming mulberry juice on atopic dermatitis in children and adolescents. The study aims to investigate the potential of mulberry fruit as a human prebiotic. This human study will recruit up to 120 participants from the Taipei Medical University Hospital (commissioned by the Ministry of Health and Welfare). Participants will be divided into experimental groups and a control group, with a 3-month intervention involving five clinical assessments and three stool collections. The goal is to compare the severity of atopic dermatitis, gut microbiota, and metabolite changes during the 6 days of mulberry juice consumption between the experimental and control groups.\n\nThis project will help establish mulberry fruit as a potential human prebiotic and adjunctive treatment for alleviating atopic dermatitis in children.",[26,329],"Atopic Dermatitis, Probiotics","2025-05-20",{"date":332,"type":34},"2025-05-25",{"date":334,"type":34},"2025-03-17",{"date":336,"type":20},"2026-04-30",{"name":338,"class":41},"Taipei Medical University Shuang Ho Hospital",{"id":340,"slug":341,"hasResults":11,"nctId":342,"briefTitle":343,"officialTitle":344,"acronym":4,"eligibilityCriteria":345,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":346,"enrollmentInfo":347,"targetDuration":4,"studyType":75,"phases":349,"briefSummary":351,"conditions":352,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":356,"lastUpdatePostDateStruct":357,"startDateStruct":359,"completionDateStruct":361,"leadSponsor":363,"locationsCount":42},"100581438","phase-2-herbal-ointment-in-treating-atopic-dermatitis-topically-100581438","NCT06850311","Herbal Ointment in Treating Atopic Dermatitis Topically","Efficacy and Safety of Herbal Topical Ointment in Treating Atopic Dermatitis: A Randomized, Double-Blind, Placebo-Controlled Trial","Inclusion Criteria:\n\n1. Between 18 and 65 years old, female or male.\n2. Atopic dermatitis fulfilling the diagnostic criteria of Hanifin\\&Rajka.\n3. Atopic dermatitis involving \\\u003C10% of BSA. (Base on the BSA result of Screening)\n4. An Investigator's Global Assessment (IGA) score of 2, 3 or 4 which corresponds to mild, moderate or severe disease. (Base on the IGA result of Screening)\n5. Female patients of child-bearing age with negative pregnancy test at screening.\n6. Female patients of child-bearing age that agree to continue using birth control measures approved by the investigator and agree not to lactate for the duration of the study.\n\nAgree to only receive stable doses of an additive-free, basic bland emollient for at least 7 days before baseline (day0) Willing to comply with study protocol and agree to sign an informed consent form.\n\nExclusion Criteria:\n\n1. Having a history of topical or systematical hypersensitivity to herbal or its excipient (e.g. vehicle) in ointment\n2. Undergoing phototherapy (e.g. UVB, PUVA) or systemic therapy (e.g. Immunosuppressive agents) within 30 days.\n3. Having used topical or oral therapy (e.g. topical corticosteroids, antibiotic, TCM) for dermatitis within 7 days before the first application of the study medication.\n4. Having a significant concurrent disease, such as: significant abnormalities in hematology, severe uncontrolled metabolic syndrome (e.g., hypertension, diabetes mellitus, metabolic arthritis, hyperthyroidism), psychiatric disease, cancer or AIDS.\n5. Having abnormal liver or renal function (AST\u002FALT \\>3 x ULN, creatinine \\>2.0 mg\u002Fdl).\n6. Women who are lactating, pregnant or preparing to be pregnant.","65 Years",{"count":348,"type":20},66,[106,350],"PHASE3","Atopic dermatitis (AD), also known as atopic eczema, is a chronic inflammatory skin disorder. The current first-line recommended treatment for AD is the use of emollients, topical corticosteroids (TCS), and oral antihistamines if necessary. However, patients often have side effects like skin atrophy and telangiectasia. And there were plenty of herbal medicine which are beneficial to atopic dermatitis in ancient Chinese medicine books and records. Therefore, the purpose of this study is to develop a new topical application of traditional Chinese medicine and evaluate its clinical efficacy in AD patients. In human trial, 66 Subjects diagnosed as AD will be enrolled and treated with Sophora flavescens Aiton topical ointment. After treatment we will estimate the efficacy and record adverse events to conduct statistically analysis.\n\nThe 1st year project: (1) Expect to enroll 66 clinical subjects of AD. (2) Evaluate subjects 'symptom and proceed herbal ointment treatment. (3) Record treatment responses including adverse effect. (4) Conduct statistically analysis.\n\nThe 2nd year project: (1) Completing enrollment of 66 clinical subjects of AD. (2) Finish evaluation and treatment of all subjects. (3) Statistically analysis all collecting data (4) Discuss and analyze the outcome.",[109,25,26,110,353,116,354,355],"TCM","Skin Diseases, Eczematous","Skin Diseases, Genetic","2025-02-23",{"date":358,"type":34},"2025-02-27",{"date":360,"type":20},"2025-03-01",{"date":362,"type":20},"2027-04-01",{"name":364,"class":41},"En Chu Kong Hospital",{"id":366,"slug":367,"hasResults":11,"nctId":368,"briefTitle":369,"officialTitle":370,"acronym":371,"eligibilityCriteria":372,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":373,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":375,"conditions":376,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":378,"lastUpdatePostDateStruct":379,"startDateStruct":381,"completionDateStruct":383,"leadSponsor":385,"locationsCount":42},"100463600","china-type-ii-inflammatory-skin-disease-clinical-research-and-standardized-diagnosis-and-treatment-project-100463600","NCT05316805","China Type II Inflammatory Skin Disease Clinical Research and Standardized Diagnosis and Treatment Project","China Type II Inflammatory Skin Disease Clinical Research and Standardized Diagnosis and Treatment Project: a National Multicenter Prospective Cohort Study","CORNERSTONE","Inclusion Criteria:\n\n1. Patients from the medical units that has passed the data review of the National Clinical Center for Skin and Immune Diseases (see the study sites for data collection for details);\n2. patients diagnosed with type 2 inflammatory skin diseases (dermatitis\u002Feczema, urticaria, pemphigoid, prurigo nodularis).\n\nExclusion Criteria:\n\n1. patients who fail to provide informed consent form;\n2. patients who cannot complete the questionnaire independently or under the guidance of investigators",{"count":374,"type":20},100000,"In order to further improve the diagnosis and treatment level of type 2 inflammatory skin diseases, the National Clinical Center for Skin and Immune Diseases established a standardized diagnosis and treatment center for type 2 inflammatory skin diseases to systematically and effectively understand the current treatment status of patients with type 2 inflammatory skin diseases, as well as the efficacy and safety of various treatment methods during practices, so as to further improve the diagnosis and treatment level of type 2 inflammatory skin diseases and help patients with type 2 inflammatory skin diseases.",[110,377],"Prurigo Nodularis","2024-08-13",{"date":380,"type":34},"2024-08-15",{"date":382,"type":34},"2021-08-31",{"date":384,"type":20},"2031-12-31",{"name":386,"class":41},"Peking University First Hospital",{"id":388,"slug":389,"hasResults":11,"nctId":390,"briefTitle":391,"officialTitle":392,"acronym":4,"eligibilityCriteria":393,"healthyVolunteers":50,"sex":16,"minAge":394,"maxAge":395,"enrollmentInfo":396,"targetDuration":4,"studyType":75,"phases":398,"briefSummary":399,"conditions":400,"keywords":403,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":407,"lastUpdatePostDateStruct":408,"startDateStruct":410,"completionDateStruct":411,"leadSponsor":412,"locationsCount":42},"100551042","impact-of-regular-consumption-of-eggs-and-nutrients-fortified-eggs-on-eczema-condition-in-singapore-individuals-100551042","NCT06454942","Impact of Regular Consumption of Eggs and Nutrients Fortified Eggs on Eczema Condition in Singapore Individuals","Impact of Regular Consumption of Eggs and Nutrients Fortified Eggs on Eczema Condition in Singapore Individuals With Eczema","Inclusion Criteria:\n\n1. English-literate and able to give informed consent in English\n2. Male and female participants, aged between 21 and 59 inclusive\n3. Healthy individuals with no underlying condition or on regular medication\n4. BMI between 18.5-25 kg\u002Fm2\n5. Mild to moderate severity of eczema, which will also be determined using our questionnaires during the screening visit\n\nExclusion Criteria:\n\n1. Significant change in body weight (3 kg or more) in the past 3 months\n2. Significant exercise pattern over the past 3 months defined as high-intensity exercise of more than 3 hours per week\n3. Known food allergy to eggs\n4. Taking dietary supplements which may impact the study results\n5. Having gastrointestinal disorders not suitable for the study\n6. Current smokers\n7. Consumes more than 2 alcoholic drinks per day i.e. one drink is defined as either 150ml of wine, 340ml of beer\u002Fcider, or 45ml of distilled spirit\n8. Taking lipid-lowering and blood pressure-controlling medications for less than 3 years\n9. Pregnant or lactating women, or planning to conceive in the next 6 months\n10. Unwilling to stop the medication of eczema during the study, either topical creams or oral medications\n11. Hierarchical link (professional and familial ties) with the research team members\n12. Participating in another clinical study\n13. Having blindness in one eye or more, eye diseases, retinal\u002Flens\u002Foptical nerve surgery, or other eye conditions that may impact the study results\n14. Low-quality macular pigment optical density results were determined during the screening visit.","21 Years","59 Years",{"count":397,"type":20},44,[218],"The study aims to assess the effects of daily consumption of nutrients-fortified eggs on eczema condition in Singapore individuals with eczema. The investigators hypothesize that egg consumption will improve eczema condition and nutrients fortified egg consumption will improve further improvements when compared to standard egg consumption in individuals with eczema",[110,401,402],"Aging","Diet Modification",[109,111,404,405,406],"Young and Middle-aged adults","Eye health","Antioxidants","2024-07-17",{"date":409,"type":34},"2024-07-19",{"date":407,"type":34},{"date":178,"type":20},{"name":413,"class":41},"National University of Singapore"]